Is END or ABBV a better dividend investment in 2026?

END currently yields 1277.96% with a 5% 5-year dividend growth rate. ABBV yields 3.67% with 8.9% growth. The better choice depends on your goal: END offers higher current income.

What is the dividend yield difference between END and ABBV?

END has a forward dividend yield of 1277.96% ($2.00/share annually). ABBV yields 3.67% ($6.20/share annually). The yield gap is 1274.29 percentage points.

Home › Compare › END vs ABBV

END vs ABBV: Dividend Comparison 2026

END yields 1277.96% · ABBV yields 3.67%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 END wins by $164974646.57M in total portfolio value

INVESTMENT

TIME HORIZON10 years

END

● Live price

1277.96%

Share price

$0.16

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$164974646.61M

Annual income

$142,967,688,417,487.44

Full END calculator →

ABBV

AbbVie Inc.

● Live price

3.67%

Share price

$168.90

Annual div

$6.20

5Y div CAGR

8.9%

Payout ratio

58%

After 10 yrs · $10,000 · DRIP

Portfolio value

$39.9K

Annual income

$1,154.43

Full ABBV calculator →

Portfolio growth — END vs ABBV

📍 END pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	END	ABBV
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, END + ABBV cover 4 of 12 months — good coverage

Jan

ABBV

Feb

—

Mar

—

Apr

ABBV

May

—

Jun

—

Jul

ABBV

Aug

—

Sep

—

Oct

ABBV

Nov

—

Dec

—

END pays

ABBV pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

END

Annual income on $10K today (after 15% tax)

$108,626.20/yr

After 10yr DRIP, annual income (after tax)

$121,522,535,154,864.31/yr

ABBV

Annual income on $10K today (after 15% tax)

$312.02/yr

After 10yr DRIP, annual income (after tax)

$981.27/yr

At 15% tax rate, END beats the other by $121,522,535,153,883.05/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of END + ABBV for your $10,000?

END: 50%ABBV: 50%

100% ABBV50/50100% END

Portfolio after 10yr

$82487323.32M

Annual income

$71,483,844,209,320.94/yr

Blended yield

86.66%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

END

No analyst data

ABBV

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$256.15

+51.7% upside vs current

Range: $223.00 — $299.00

Altman Z

2.0

Piotroski

8/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

END buys

ABBV buys

No recent congressional trades found for END or ABBV in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricENDABBV

Forward yield	1277.96% ✓	3.67%
Annual dividend / share	$2.00	$6.20 ✓
Payout ratio	50% ✓	58%
1-year div growth	0%	4.7% ✓
5-year div CAGR	0%	8.9% ✓
Portfolio after 10y	$164974646.61M ✓	$39.9K
Annual income after 10y	$142,967,688,417,487.44 ✓	$1,154.43
Total dividends collected	$163344807.33M ✓	$7.2K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: END vs ABBV ($10,000, DRIP)

Year	END Portfolio	END Income/yr	ABBV Portfolio	ABBV Income/yr	Gap
1← crossover	$138,496	$127,795.53	$11,520	$399.75	+$127.0K → END
2	$1,802,313	$1,654,122.33	$13,261	$450.98	+$1.79M → END
3	$22,046,169	$20,117,694.24	$15,255	$508.41	+$22.03M → END
4	$253,573,307	$229,983,906.30	$17,536	$572.74	+$253.56M → END
5	$2,743,526,143	$2,472,202,704.53	$20,145	$644.78	+$2743.51M → END
6	$27,933,607,769	$24,998,034,796.65	$23,126	$725.38	+$27933.58M → END
7	$267,759,149,710	$237,870,189,396.55	$26,532	$815.52	+$267759.12M → END
8	$2,417,453,617,589	$2,130,951,327,399.63	$30,420	$916.26	+$2417453.59M → END
9	$20,567,250,646,227	$17,980,575,275,406.47	$34,855	$1,028.80	+$20567250.61M → END
10	$164,974,646,608,950	$142,967,688,417,487.44	$39,914	$1,154.43	+$164974646.57M → END

END vs ABBV: Complete Analysis 2026

END — Stock

END is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in END shares.

Full END Calculator →

ABBV — Healthcare

AbbVie is a pharmaceutical giant best known for Humira and newer blockbusters Skyrizi and Rinvoq. A Dividend Aristocrat with 52+ years of consecutive dividend increases. Strong free cash flow generation supports its above-average yield. The company's diversified pipeline reduces dependence on any single drug.

Full ABBV Calculator →

📬

Get this END vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

END vs SCHD END vs JEPI END vs O END vs KO END vs MAIN END vs JNJ END vs MRK END vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.